FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.

Elaine Chang,Yutao Gong,Chana Weinstock,Laura L. Fernandes,Jessica Hawley,Thomas Gwise,Meredith M. Regan,Toni K. Choueiri,Brian I. Rini,David F. McDermott,Michael B. Atkins,Daniel L. Suzman,Amna Ibrahim,Shenghui Tang,Marc Robert Theoret,Paul G. Kluetz,Richard Pazdur,Julia A. Beaver

FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.

2020

Elaine Chang
Yutao Gong
Chana Weinstock
Laura L. Fernandes
Jessica Hawley
Thomas Gwise
Meredith M. Regan
Toni K. Choueiri
Brian I. Rini
David F. McDermott
Michael B. Atkins
Daniel L. Suzman
Amna Ibrahim
Shenghui Tang
Marc Robert Theoret
Paul G. Kluetz
Richard Pazdur
Julia A. Beaver

5081Background: Time to treatment discontinuation (TTD) has been proposed as a potential pragmatic real-world data (RWD) endpoint, and was closely correlated with progression-free survival (PFS) in...

Keywords:

Discontinuation
Renal cell carcinoma
Oncology
time to treatment
pooled analysis
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations